Literature DB >> 33718357

Transcriptome Analysis of Dnmt3l Knock-Out Mice Derived Multipotent Mesenchymal Stem/Stromal Cells During Osteogenic Differentiation.

Chih-Yi Yang1, Rita Jui-Hsien Lu2,3, Ming-Kang Lee1, Felix Shih-Hsian Hsiao1,4, Ya-Ping Yen1,5, Chun-Chun Cheng1, Pu-Sheng Hsu1, Yi-Tzang Tsai1, Shih-Kuo Chen6, I-Hsuan Liu7, Pao-Yang Chen2, Shau-Ping Lin1,8,9,10.   

Abstract

Multipotent mesenchymal stem/stromal cells (MSCs) exhibit great potential for cell-based therapy. Proper epigenomic signatures in MSCs are important for the maintenance and the subsequent differentiation potential. The DNA methyltransferase 3-like (DNMT3L) that was mainly expressed in the embryonic stem (ES) cells and the developing germ cells plays an important role in shaping the epigenetic landscape. Here, we report the reduced colony forming ability and impaired in vitro osteogenesis in Dnmt3l-knockout-mice-derived MSCs (Dnmt3l KO MSCs). By comparing the transcriptome between undifferentiated Dnmt3l KO MSCs and the MSCs from the wild-type littermates, some of the differentially regulated genes (DEGs) were found to be associated with bone-morphology-related phenotypes. On the third day of osteogenic induction, differentiating Dnmt3l KO MSCs were enriched for genes associated with nucleosome structure, peptide binding and extracellular matrix modulation. Differentially expressed transposable elements in many subfamilies reflected the change of corresponding regional epigenomic signatures. Interestingly, DNMT3L protein is not expressed in cultured MSCs. Therefore, the observed defects in Dnmt3l KO MSCs are unlikely a direct effect from missing DNMT3L in this cell type; instead, we hypothesized them as an outcome of the pre-deposited epigenetic signatures from the DNMT3L-expressing progenitors. We observed that 24 out of the 107 upregulated DEGs in Dnmt3l KO MSCs were hypermethylated in their gene bodies of DNMT3L knock-down ES cells. Among these 24 genes, some were associated with skeletal development or homeostasis. However, we did not observe reduced bone development, or reduced bone density through aging in vivo. The stronger phenotype in vitro suggested the involvement of potential spreading and amplification of the pre-deposited epigenetic defects over passages, and the contribution of oxidative stress during in vitro culture. We demonstrated that transient deficiency of epigenetic co-factor in ES cells or progenitor cells caused compromised property in differentiating cells much later. In order to facilitate safer practice in cell-based therapy, we suggest more in-depth examination shall be implemented for cells before transplantation, even on the epigenetic level, to avoid long-term risk afterward.
Copyright © 2021 Yang, Lu, Lee, Hsiao, Yen, Cheng, Hsu, Tsai, Chen, Liu, Chen and Lin.

Entities:  

Keywords:  DNA methylation; DNMT3L; bone-marrow MSCs; epigenetics; osteogenesis

Year:  2021        PMID: 33718357      PMCID: PMC7947861          DOI: 10.3389/fcell.2021.615098

Source DB:  PubMed          Journal:  Front Cell Dev Biol        ISSN: 2296-634X


  90 in total

1.  Mesenchymal progenitor cells in human umbilical cord blood.

Authors:  A Erices; P Conget; J J Minguell
Journal:  Br J Haematol       Date:  2000-04       Impact factor: 6.998

2.  Dnmt3L and the establishment of maternal genomic imprints.

Authors:  D Bourc'his; G L Xu; C S Lin; B Bollman; T H Bestor
Journal:  Science       Date:  2001-11-22       Impact factor: 47.728

3.  Oxygen saturation in the bone marrow of healthy volunteers.

Authors:  Jonathan S Harrison; Pranela Rameshwar; Vicotr Chang; Persis Bandari
Journal:  Blood       Date:  2002-01-01       Impact factor: 22.113

4.  Epigenetic patterns of embryonic and adult stem cells.

Authors:  Noga Bloushtain-Qimron; Jun Yao; Michail Shipitsin; Reo Maruyama; Kornelia Polyak
Journal:  Cell Cycle       Date:  2009-03-26       Impact factor: 4.534

5.  Dnmt3L antagonizes DNA methylation at bivalent promoters and favors DNA methylation at gene bodies in ESCs.

Authors:  Francesco Neri; Anna Krepelova; Danny Incarnato; Mara Maldotti; Caterina Parlato; Federico Galvagni; Filomena Matarese; Hendrik G Stunnenberg; Salvatore Oliviero
Journal:  Cell       Date:  2013-09-26       Impact factor: 41.582

6.  Structural basis for recognition of H3K4 methylation status by the DNA methyltransferase 3A ATRX-DNMT3-DNMT3L domain.

Authors:  Junji Otani; Toshiyuki Nankumo; Kyohei Arita; Susumu Inamoto; Mariko Ariyoshi; Masahiro Shirakawa
Journal:  EMBO Rep       Date:  2009-10-16       Impact factor: 8.807

Review 7.  Sources and Clinical Applications of Mesenchymal Stem Cells: State-of-the-art review.

Authors:  Roberto Berebichez-Fridman; Pablo R Montero-Olvera
Journal:  Sultan Qaboos Univ Med J       Date:  2018-12-19

Review 8.  Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes.

Authors:  Reza Abdi; Paolo Fiorina; Chaker N Adra; Mark Atkinson; Mohamed H Sayegh
Journal:  Diabetes       Date:  2008-07       Impact factor: 9.461

Review 9.  Role of fibroblast growth factors in bone regeneration.

Authors:  Pornkawee Charoenlarp; Arun Kumar Rajendran; Sachiko Iseki
Journal:  Inflamm Regen       Date:  2017-08-01

10.  Mesenchymal stem cells.

Authors:  A I Caplan
Journal:  J Orthop Res       Date:  1991-09       Impact factor: 3.494

View more
  1 in total

Review 1.  Epigenetic therapy targeting bone marrow mesenchymal stem cells for age-related bone diseases.

Authors:  Yi Zhao; Jiawei He; Tao Qiu; Haoyu Zhang; Li Liao; Xiaoxia Su
Journal:  Stem Cell Res Ther       Date:  2022-05-16       Impact factor: 8.079

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.